Remove Bioavailability Remove Contract Manufacturing Remove Drug Delivery Remove Production
article thumbnail

Nanoparticles: Emerging Stars for Pharmaceutical Industry

Roots Analysis

Over the last decade, one of the major challenges faced by pharmaceutical players across the globe is low drug solubility. In fact, it has been observed that around 40% of the pharmaceutical products approved by regulatory organizations exhibit poor bioavailability / solubility.

article thumbnail

Biopharmaceutical Excipient Manufacturing – Current Scenario and Future Trends

Roots Analysis

In fact, over 8,000 biological pharmaceutical products are currently under clinical investigation worldwide. Therefore, a variety of excipients, which are pharmacologically inert substances themselves, are used to stabilize biologics during the manufacturing process and storage. Our Social Media Platform. Web: [link]. Twitter: [link].

article thumbnail

XPhyto Announces Drug Formulation Strategy and 2021 Milestones Innovation to Impact

The Pharma Data

CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT ) (“ XPhyto ” or the “ Company “) is pleased to announce its drug formulation and delivery business strategy and milestones for 2021. Pending positive results, the Company plans to advance the products toward a final pivotal study and application for regulatory approval.

Drugs 52